Delivery Order SPE2DR25D3012-SPE2DR26F4C5C
Award Date 11/28/25
Potential Completion Date 12/19/25
Potential Value $63K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $29,496.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This non-set-aside competitive award is scheduled for completion by August 18, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical used primarily for treating multiple sclerosis, reflecting the federal government's ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Ocrevus 300 mg/10 mL vials totaling $25,332.96 with completion targeted for December 31, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a contract ceiling value of $43,178.96 under firm fixed price terms. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 25, 2025, with a contract ceiling value of $24,038.58 and an ultimate completion date of September 16, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under DLA's procurement processes. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials, with a ceiling value of $24,038.58 and a firm fixed price structure. This delivery order is a non-set-aside competitive award with a completion deadline of December 1, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody used primarily to treat...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency (DLA) awarded a $48,077.16 delivery order to AmerisourceBergen Drug Corp for 4,569,852,928 units of Ocrevus 300 mg/10 ml vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for completion by November 19, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ocrevus (ocrelizumab) is a monoclonal antibody therapeutic used to treat multiple...
- The Defense Logistics Agency awarded a $53,535.55 delivery order to AmerisourceBergen Drug Corp for 4,569,471,727 units of Ocrevus 300 mg/10 mL vials on September 16, 2025, with an ultimate completion date of October 7, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody treatment used primarily for multiple sclerosis, reflecting the...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on December 16, 2025. The contract, valued at $99,008.08, is a firm fixed-price delivery order with an ultimate completion date of January 8, 2026. This award is being executed under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $126.7K to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody used in the treatment of multiple sclerosis and represents a specialized...